Benitec Biopharma Inc.
BNTC
$11.50
-$0.18-1.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.92% | -77.21% | -242.10% | -118.60% | -40.51% |
| Total Depreciation and Amortization | 48.15% | 29.67% | 29.67% | 17.78% | 1.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 210.83% | 1,090.80% | 2,862.78% | 1,252.60% | 2,425.53% |
| Change in Net Operating Assets | 192.74% | 696.23% | -738.89% | 264.21% | -148.13% |
| Cash from Operations | 50.98% | 26.93% | -149.41% | 49.97% | -43.58% |
| Capital Expenditure | 8.33% | -- | -- | 96.65% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 8.33% | -- | -- | 96.65% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 484.69% | -- | -1.61% | -- | 45,725.64% |
| Repurchase of Common Stock | -- | -- | -- | -23,156.41% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -313,150.00% | -- | -1,241.46% | 96,012.82% | -- |
| Cash from Financing | 449.69% | -- | -93.65% | -- | 45,720.51% |
| Foreign Exchange rate Adjustments | -146.32% | 190.53% | -2,300.00% | -118.26% | 274.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 803.36% | -119.23% | -115.74% | 505.99% | 290.20% |